Retatrutide Side Effects: Complete Guide

Retatrutide Side Effects: A Complete Guide

Retatrutide is an investigational medication being studied for weight management and type 2 diabetes. As of October 2026 it is not approved anywhere and is only available inside clinical trials; there is no official prescribing label yet, so the information below comes from published trial results. As a triple-agonist that targets three different hormone receptors (GIP, GLP-1, and glucagon), it represents a new approach in metabolic health. As with any medication, understanding its potential side effects is a crucial part of making an informed decision with your doctor.

This guide offers a clear and balanced overview of the side effects observed in clinical trials for retatrutide. The goal is to provide information, not medical advice, to help you have a productive conversation with your healthcare team. Consult your healthcare provider before starting any medication.

Understanding the Side Effect Profile

Medications that work on metabolic hormones, including the class of drugs known as incretin mimetics (like GLP-1 agonists), often share a similar side effect profile. The most frequently reported side effects of retatrutide are related to the gastrointestinal (digestive) system.

This is largely due to how the medication works. By slowing down how quickly your stomach empties, it helps you feel full for longer, but this can also lead to digestive discomfort. The good news is that for many people, these side effects are mild to moderate in intensity and tend to lessen over time as the body adjusts.

Clinical trials typically use a dose-escalation approach, meaning you start on a lower dose that is gradually increased. This strategy is designed specifically to help your body adapt and to improve tolerability.

Common Side Effects of Retatrutide

The most common side effects reported in clinical studies are gastrointestinal in nature. They were more frequently reported at higher doses. In the Phase 3 TRIUMPH-1 trial, for example, nausea was reported by 28.6%, 38.4% and 42.4% of people on 4 mg, 9 mg and 12 mg, compared with 14.8% on placebo, and vomiting by 10.6%, 22.8% and 25.3% compared with 4.8%. Stopping treatment because of side effects ranged from 4.1% (4 mg) to 11.3% (12 mg), compared with 4.9% on placebo.

Gastrointestinal (GI) Issues

• Nausea: This is often the most reported side effect. It may feel like a mild, persistent queasiness or come in waves, particularly after eating.
• Diarrhea: Some individuals may experience looser or more frequent stools. Staying hydrated is important if this occurs.
• Vomiting: While less common than nausea or diarrhea, vomiting was also reported, especially at higher doses.
• Constipation: On the other end of the spectrum, some people may experience constipation.
• Decreased Appetite: This is an intended effect of the medication that contributes to weight loss, but it's important to ensure you're still getting adequate nutrition.
• Abdominal Discomfort or Indigestion: Feelings of bloating, gas, or general stomach upset can occur.

For many users, these GI side effects are most noticeable when starting the medication or after a dose increase. They often improve significantly within a few weeks as the body gets used to the treatment.

Other Reported Side Effects

Beyond the digestive system, other side effects have been noted in clinical trials.

Dysesthesia (Unusual Skin Sensations)

Phase 3 trials reported dysesthesia, an unusual or unpleasant skin sensation such as tingling, burning or sensitivity to touch. In TRIUMPH-4 (adults with obesity and knee osteoarthritis) it was reported by 8.8% on 9 mg and 20.9% on 12 mg, compared with 0.7% on placebo. It was generally mild to moderate and rarely led to stopping treatment. This effect is not typical of other GLP-1 medicines, so it is worth mentioning to the study team if it happens.

Increased Heart Rate

Some participants in studies experienced a dose-dependent increase in their resting heart rate. In the Phase 2 trial this rise peaked at around 24 weeks and then declined. It is something the study doctors monitor. It’s important to let them know if you experience feelings of a racing or pounding heart.

Injection Site Reactions

Since retatrutide is administered as an injection, some people may experience mild reactions at the injection site. This can include redness, itching, swelling, or slight pain.

Fatigue and Headaches

Fatigue, or feeling unusually tired, and headaches have also been reported. These are common side effects across a wide range of medications and may be temporary.

Pregnancy

Retatrutide has not been studied in pregnancy. Tell the study team straight away if you become pregnant or are planning a pregnancy.

Serious but Less Common Side Effects

While the majority of side effects are mild to moderate, it is important to be aware of the potential for more serious adverse events. These are much less common but require prompt medical attention.

Pancreatitis

Inflammation of the pancreas (pancreatitis) is a rare but serious risk associated with this class of medications. Seek immediate medical care if you develop severe, persistent pain in your abdomen that may radiate to your back, with or without vomiting.

Gallbladder Problems

Certain medications for weight management can increase the risk of gallbladder issues, such as gallstones or inflammation. Symptoms can include pain in your upper stomach area, fever, nausea, vomiting, or yellowing of the skin or eyes (jaundice). Contact a doctor promptly if these occur.

Kidney Problems

In people who experience severe nausea, vomiting, or diarrhea, dehydration can occur. Severe dehydration can sometimes lead to acute kidney injury. Drink enough fluids, and seek medical help if vomiting or diarrhoea stops you keeping fluids down.

Thyroid C-Cell Tumors

Approved long-acting GLP-1 medicines, such as semaglutide and tirzepatide, carry a US boxed warning about thyroid C-cell tumors. This is based on studies in rodents where the drugs caused these tumors. It is not known whether this happens in humans. Because of this potential risk, retatrutide would likely be contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Serious Allergic Reactions

As with any drug, there is a very small risk of a serious allergic reaction (anaphylaxis). Seek emergency medical help if you experience symptoms like swelling of your face, lips, tongue, or throat; problems breathing or swallowing; a severe rash or itching; fainting or feeling dizzy; or a very rapid heartbeat.

Low Blood Sugar

In people with type 2 diabetes who also take insulin or a sulfonylurea, medicines like this can increase the risk of low blood sugar. Signs include shakiness, sweating, confusion and a fast heartbeat.

When to Contact Your Healthcare Professional

Open communication with your doctor is key to a safe and successful treatment journey.

• If you are in a trial, report all side effects to the study team, who will advise on any dose change.
• For mild side effects that are manageable, you can typically discuss them at your next scheduled appointment.
• For side effects that are persistent or bothersome, don't hesitate to call your provider’s office for guidance. They may have strategies to help you manage them.
• For any symptoms that feel severe or for signs of a serious side effect (like severe abdominal pain or difficulty breathing), you should seek medical attention immediately.

Your clinician can help you weigh the benefits and risks of any treatment and determine if it is the right choice for your individual health circumstances. They are your best resource for personalized information and support. Consult your healthcare provider before starting any medication.

Sources

• New England Journal of Medicine — retatrutide phase 2 trial: https://www.nejm.org/doi/full/10.1056/NEJMoa2301972
• PubMed record for retatrutide phase 2 obesity results: https://pubmed.ncbi.nlm.nih.gov/37366315/
• ClinicalTrials.gov — TRIUMPH-1 study NCT05929066: https://clinicaltrials.gov/study/NCT05929066
• AJMC — TRIUMPH-1 topline results, including side-effect rates (May 2026): https://www.ajmc.com/view/retatrutide-achieves-up-to-30-3-average-weight-loss-in-phase-3-triumph-1-trial
• Patient Care — TRIUMPH-4 results, including dysesthesia and discontinuation rates (December 2025): https://www.patientcareonline.com/view/retatrutide-achieves-up-to-28-7-weight-loss-and-marked-knee-pain-reduction-in-phase-3-triumph-4-trial
• PubMed — TRIUMPH-1 publication, NEJM 2026: https://pubmed.ncbi.nlm.nih.gov/42814954/